Posted by Michael Wonder on 25 Oct 2022
New FDA approved labelling for Petros Pharmaceuticals’ Stendra (avanafil) now includes efficacy data regarding use in men who have undergone radical prostatectomy
25 October 2022 - Expanded Stendra labelling now includes data on a significant population of men not previously included following submission of additional clinical trial data.
Petros Pharmaceuticals today announces the expansion of the FDA labelling for its oral erectile dysfunction drug, Stendra (avanafil), marketed by its subsidiary, Metuchen Pharmaceuticals.
